ArticleNature communications2023
A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 76 citations in OpenAlex.
- Role of bacterial outer membrane vesicles in immune evasion during infection.Archives of microbiology · 2026Review
- Targeting Outer Membrane Vesicles ofJournal of microbiology and biotechnology · 2026Review
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- New insights into outer membrane vesicles in Gram-negative bacteria from biogenesis to applications.Communications biology · 2026Review
- Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Bacterial extracellular vesicles as recyclable nutrient reservoirs.Nature communications · 2026Article
- Outer membrane vesicles: Versatile nanocarriers for therapeutic delivery and immune modulation.Acta pharmaceutica Sinica. B · 2026Review
- Bacterial Extracellular Vesicles in Biomedical Research and Clinical Translation.Microbial biotechnology · 2026Review
- Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.Nature biomedical engineering · 2026Article
- Outer membrane vesicles fromMicrobiology spectrum · 2026Article
- Bacterial extracellular vesicles as bioactive nanocarriers for wound treatment.Acta pharmaceutica Sinica. B · 2026Review
- Light-assisted drying enables vaccine stabilization and supports cold-chain-independent distribution.Scientific reports · 2026Article
- Bioengineering modification and application of bacterial outer membrane vesicles.International journal of medical sciences · 2026Review
- 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026Review
- Engineering Bacterial Extracellular Vesicles as Nanoweapons to Fight against Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.Frontiers in immunology · 2026Review
- Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.Biomaterials research · 2026Review
- Programmable nanomotor system responsively and chemotactically captures tumor associated antigens for enhancedMaterials today. Bio · 2025Article
- Bacterial outer membrane vesicles: a novel target in mediating bacterial infection and host immune responses.World journal of microbiology & biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
Engineered outer membrane vesicles (OMVs) derived from Gram-negative bacteria are a promising technology for the creation of non-infectious, nanoparticle vaccines against diverse pathogens. However, antigen display on OMVs can be difficult to control and highly variable due to bottlenecks in protein expression and localization to the outer membrane of the host cell, especially for bulky and/or complex antigens. Here, we describe a universal approach for avidin-based vaccine antigen crosslinking (AvidVax) whereby biotinylated antigens are linked to the exterior of OMVs whose surfaces are remodeled with multiple copies of a synthetic antigen-binding protein (SNAP) comprised of an outer membrane scaffold protein fused to a biotin-binding protein. We show that SNAP-OMVs can be readily decorated with a molecularly diverse array of biotinylated subunit antigens, including globular and membrane proteins, glycans and glycoconjugates, haptens, lipids, and short peptides. When the resulting OMV formulations are injected in mice, strong antigen-specific antibody responses are observed that depend on the physical coupling between the antigen and SNAP-OMV delivery vehicle. Overall, these results demonstrate AvidVax as a modular platform that enables rapid and simplified assembly of antigen-studded OMVs for application as vaccines against pathogenic threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.